close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aligos Therapeutics, Inc. - Common stock (NQ:ALGS)

5.360 -0.040 (-0.74%)
Delayed Quote Updated: 11:08 AM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aligos Therapeutics, Inc. - Common stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2024 Financial Results
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics to Announce 2nd Quarter 2024 Financial Results on August 6, 2024
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Week In Review: Nanjing Triastek Partners With BioNTech In A $1.2 Billion Drug Development Deal ↗
Triastek will develop oral RNA therapeutics with Germany’s BioNTech based on its 3D printing technology. Triastek will receive a $10 million upfront payment and up to $1.2 billion in milestones, plus... 
Via Talk Markets
News headline image
Aligos Therapeutics Announces Clinical Collaboration with Xiamen Amoytop Biotech Co., Ltd.
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Recap: Aligos Therapeutics Q4 Earnings ↗
 
Via Benzinga
News headline image
Aligos Therapeutics Earnings Preview ↗
 
Via Benzinga
News headline image
Aligos Therapeutics to Host KOL Event to Discuss the Positive Phase 1b Data from ALG-000184 for the Treatment of CHB
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Presents Positive Data at the EASL Congress 2024
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH
From Aligos Therapeutics
Via GlobeNewswire
News headline image
ALGS Stock Earnings: Aligos Therapeutics Misses EPS for Q1 2024 ↗
ALGS stock results show that Aligos Therapeutics missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
From Aligos Therapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Earnings Scheduled For March 12, 2024 ↗
Companies Reporting Before The Bell • Aurora Mobile (NASDAQ:JG) is likely to report earnings for its fourth quarter. 
Via Benzinga
News headline image
Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024
Event to feature KOL perspective on emerging MASH therapies 
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Strengthens Finance Leadership Team with Two New Appointments
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Why Hello Group Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket ↗
Shares of Hello Group Inc. (NASDAQ: MOMO) jumped in pre-market trading after reporting results for the third quarter. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Aligos Therapeutics Presents Positive Clinical Data at Hep-DART 2023 from Phase 1 Studies in HBV (ALG-000184) and NASH (ALG-055009)
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics To Present at the Piper Sandler Healthcare Conference
From Aligos Therapeutics
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.